• OncologyTube
    • 0
      • Title
        User LIVE NOW
      • Logo LIVE NOW
        Title
        User
      • Schedule An Interview
        • Schedule A Remote Interview with OncologyTube
    • Home
    • Trending

    • Sign In

    • Audios and Videos
    • Videos
    • Audios

    • Channels

    • Browse Channels

    • Categories

    • Acute Lymphoblastic Leukemia 5648
    • Acute Myelogenous Leukemia 202
    • Bladder Cancer 71
    • Bone Metastases 2
    • Brain Cancer 59
    • Breast Cancer 233
    • Business Management 3
    • Cervical Cancer 6
    • Chronic Lymphocytic Leukemia 192
    • Chronic Myelogenous Leukemia 43
    • Colorectal Cancer 110
    • COVID-19 27
    • Gastrointestinal Cancer 93
    • General 320
    • Head and Neck Cancers 74
    • Hematologic Malignancies 180
    • Hodgkin Lymphoma 28
    • Immunotherapy 155
    • Kidney Cancer 376
    • Liver Cancer 25
    • Lymphoma 180
    • Melanoma and Skin Cancer 57
    • Multiple Myeloma 466
    • Myeloproliferative Disease 20
    • News 148
    • Non-Hodgkin Lymphoma 77
    • Non-Small Cell Lung Cancer 413
    • Other 256
    • Ovarian Cancer 43
    • Pancreatic Cancer 73
    • Patient Resources 28
    • Pediatric Cancer 3
    • Prostate Cancer 225
    • Sickle Cell 21
    • Small Cell Lung Cancer 72
    • Soft Tissue Sarcoma 10
    • Supportive Care 47
    • Testicular Cancer 3
    • Urology 14
    • Uterine Cancer 7

    • About
    • Contact
    Anne L. Angiolillo, MD @ChildrensNatl #ChildhoodBALL #ChildhoodLeukemia #Cancer #Research Results From Children's Oncology Group AALL0932 Anne L. Angiolillo, MD @ChildrensNatl #ChildhoodBALL #ChildhoodLeukemia #Cancer #Research Results From Children's Oncology Group AALL0932
    00:10:17

    Anne L. Angiolillo, MD @ChildrensNatl #ChildhoodBALL #ChildhoodLeukemia #Cancer #Research Results From Children's Oncology Group AALL0932

    Anne L. Angiolillo, MD, MS, director of the Leukemia and Lymphoma Program at Children’s National Medical Center speaks about the Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932.

    Link To Study -
    https://ascopubs.org/doi/abs/10.1200/JCO.20.00494

    Abstract - 

    PURPOSITY:
    In order to optimize disease-free survival (DFS) thus reducing the burden of therapy in children with newly diagnosed NCI standard-risk (SR) B-acute lymphoblastic leukemia, AALL0932 tested two randomized maintenance approaches (B-ALL).



    AND METHODS:
    AALL0932 enrolled 9,229 patients with B-ALL; 2,364 patients with a mean risk (AR) were randomly assigned to vincristine/dexamethasone pulses every 4 (VCR/DEX4) or every 12 (VCR/DEX12) weeks and to a starting dose of 20 mg/m2 (MTX20) or 40 mg/m2 once-weekly oral methotrexate every 4 (VCR/DEX4) or every 12 (VCR/DEX12) weeks at the start of maintenance therapy (MTX40).



    RESULTATIONS:
    For all qualifying and evaluable SR B-ALL patients (n = 9,226), 5-year event-free survival and overall survival (OS) from registration were 92.0 percent (95 percent CI, 91.1 percent to 92.8 percent) and 96.8 percent (95 percent CI, 96.2 percent to 97.3 percent), respectively. For randomly allocated AR patients, the 5-year DFS and OS from the start of maintenance were 94.6 percent (95 percent CI, 93.3 percent to 95.9 percent) and 98.5 percent (95 percent CI, 97.7 percent to 99.2 percent), respectively. For patients randomly assigned to receive VCR/DEX4 (n = 1,186) versus VCR/DEX12 (n = 1,178), the 5-year DFS and OS were 94.1 percent (95 percent CI, 92.2 percent to 96.0 percent) and 98.3 percent (95 percent CI, 97.2 percent to 99.4 percent) v 95.1 percent (95 percent CI, 93.3 percent to 96.9 percent) and 98.6 percent (95 percent CI, 97.7 percent to 99.6 percent) respectively (P = 95.1 percent) v 95.1 percent (95 percent CI, 93.3 percent to 96.9 percent) For AR patients randomly assigned to receive MTX20 versus MTX40, the 5-year DFS and OS for AR patients were 95.1 percent (95 percent CI, 93.3 percent to 96.8 percent) and 98.8 percent (95 percent CI, 97.9 percent to 99.7 percent) versus 94.2 percent (95 percent CI, 92.2 percent to 96.1 percent) and 98.1 percent (95 percent CI, 97.0 percent to 99.2 percent) versus 94.2 percent (P = .92 and .89).



    Observations:
    Despite obtaining one-third of the vincristine/dexamethasone pulses previously used as standard of care in Children's Oncology Community (COG) studies, the NCI-SR AR B-ALL that obtained VCR/DEX12 had outstanding results. Compared with 20 mg/m2 once weekly, the higher starting dose of MTX of 40 mg/m2 once weekly did not boost the performance. In order to minimize the burden of therapy for patients and their families, the reduced frequency of vincristine/dexamethasone pulses has been introduced into frontline COG B-ALL trials.

    12 Views
    1 week ago
    cancernewsupdate
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Suggested

    Anne L. Angiolillo, MD @ChildrensNatl #ChildhoodBALL #ChildhoodLeukemia #Cancer #Research Results From Children's Oncology Group AALL0932 Anne L. Angiolillo, MD @ChildrensNatl #ChildhoodBALL #ChildhoodLeukemia #Cancer #Research Results From Children's Oncology Group AALL0932
    00:10:17

    Anne L. Angiolillo, MD @ChildrensNatl #ChildhoodBALL #ChildhoodLeukemia #Cancer #Research Results From Children's Oncology Group AALL0932

    Free
    12 Views
    1 week ago
    cancernewsupdate
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Trending

    Add-On Chemo Boosts Survival in High-Risk Endometrial Cancer

    Add-On Chemo Boosts Survival in High-Risk Endometrial Cancer

    Free
    95 Views
    1 year ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    TAGRISSO® (OSIMERTINIB) SIGNIFICANTLY IMPROVES OVERALL SURVIVAL IN THE PHASE III FLAURA TRIAL FOR 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER

    TAGRISSO® (OSIMERTINIB) SIGNIFICANTLY IMPROVES OVERALL SURVIVAL IN THE PHASE III FLAURA TRIAL FOR 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER

    Free
    792 Views
    1 year ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Roswell Park Researchers Identify Immune Biomarker of Response in Patients With Advanced Liver Cancer

    Roswell Park Researchers Identify Immune Biomarker of Response in Patients With Advanced Liver Cancer

    Free
    113 Views
    1 year ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Having a Parent, Sibling, or Child with Blood Cancer Increases One’s Own Risk

    Having a Parent, Sibling, or Child with Blood Cancer Increases One’s Own Risk

    Free
    207 Views
    1 year ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    • 1 (current)
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10

    Acute Lymphoblastic Leukemia

    Anne L. Angiolillo, MD @ChildrensNatl #ChildhoodBALL #ChildhoodLeukemia #Cancer #Research Results From Children's Oncology Group AALL0932 Anne L. Angiolillo, MD @ChildrensNatl #ChildhoodBALL #ChildhoodLeukemia #Cancer #Research Results From Children's Oncology Group AALL0932
    00:10:17

    Anne L. Angiolillo, MD @ChildrensNatl #ChildhoodBALL #ChildhoodLeukemia #Cancer #Research Results From Children's Oncology Group AALL0932

    Free
    12 Views
    1 week ago
    cancernewsupdate
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Michael A. Pulsipher, MD @ChildrensLA #AcuteLymphoyteLeukemia #Cancer #Research Continued Role for Radiation in the Conditioning Regimen for Children With ALL Michael A. Pulsipher, MD @ChildrensLA #AcuteLymphoyteLeukemia #Cancer #Research Continued Role for Radiation in the Conditioning Regimen for Children With ALL
    00:12:38

    Michael A. Pulsipher, MD @ChildrensLA #AcuteLymphoyteLeukemia #Cancer #Research Continued Role for Radiation in the Conditioning Regimen for Children With ALL

    Free
    10 Views
    3 weeks ago
    AnnualMeeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Christina Peters, MD @StAnna_CCRI @KidsCancerInst #ChildhoodALL  #ALL  #Cancer #Research A Multinational, Randomized, Noninferiority Phase III Study on Childhood ALL Christina Peters, MD @StAnna_CCRI @KidsCancerInst #ChildhoodALL  #ALL  #Cancer #Research A Multinational, Randomized, Noninferiority Phase III Study on Childhood ALL
    00:16:43

    Christina Peters, MD @StAnna_CCRI @KidsCancerInst #ChildhoodALL #ALL #Cancer #Research A Multinational, Randomized, Noninferiority Phase III Study on Childhood ALL

    Free
    11 Views
    1 month ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    ASH 2020: Multi-cytokine Inhibitor Shows Positive Results in Refractory Cutaneous T-Cell Lymphoma

    ASH 2020: Multi-cytokine Inhibitor Shows Positive Results in Refractory Cutaneous T-Cell Lymphoma

    Free
    5 Views
    2 months ago
    oncozine
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Impact of cytotoxics on pregnancy needs to be better understood
    00:03:58

    Impact of cytotoxics on pregnancy needs to be better understood

    Free
    8 Views
    4 months ago
    sngilani
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Transforming Cell Therapy Manufacturing by “Squeezing” Cells: An Interview with Armon Sharei
    00:44:06

    Transforming Cell Therapy Manufacturing by “Squeezing” Cells: An Interview with Armon Sharei

    Free
    6 Views
    6 months ago
    oncozine
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice - in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner - - Will... SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice - in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner - - Will...
    0:03:47

    SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice - in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner - - Will...

    Free
    24 Views
    6 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    INO-5401 and INO-9012 in combination with cemiplimab REGN2810 - What is the next step for this research? - David A. Reardon, MD Dana-Farber Cancer Institute @DanaFarber #glioblastoma INO-5401 and INO-9012 in combination with cemiplimab REGN2810 - What is the next step for this research? - David A. Reardon, MD Dana-Farber Cancer Institute @DanaFarber #glioblastoma
    0:04:13

    INO-5401 and INO-9012 in combination with cemiplimab REGN2810 - What is the next step for this research? - David A. Reardon, MD Dana-Farber Cancer Institute @DanaFarber #glioblastoma

    Free
    25 Views
    6 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Jeremy Warner, MD on Impact of COVID-19: Can Treatment go as Planned? #ASCO2020 @VUMC_Cancer Jeremy Warner, MD on Impact of COVID-19: Can Treatment go as Planned? #ASCO2020 @VUMC_Cancer
    0:04:18

    Jeremy Warner, MD on Impact of COVID-19: Can Treatment go as Planned? #ASCO2020 @VUMC_Cancer

    Free
    15 Views
    7 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Acute Lymphocytic Leukemia: Overview of Latest Guidelines in Hematological Malignancies
    00:28:37

    Acute Lymphocytic Leukemia: Overview of Latest Guidelines in Hematological Malignancies

    Free
    32 Views
    10 months ago
    HMP CME
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Epigenetic Therapy for Lymphoma: From the Laboratory to the Clinic
    00:22:33

    Epigenetic Therapy for Lymphoma: From the Laboratory to the Clinic

    Free
    12 Views
    10 months ago
    HMP CME
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Acute Myeloid Leukemia: Debate on Standard of Care for Patients ≥ 60 Years
    00:17:34

    Acute Myeloid Leukemia: Debate on Standard of Care for Patients ≥ 60 Years

    Free
    11 Views
    10 months ago
    HMP CME
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    • 1 (current)
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10

    Copyright 2020 Medicus Networks, Inc. 27574 Commerce Center Drive, Suite 236, Temecula, CA 92592